Corticosteroids, central serous chorioretinopathy, and neurocysticercosis.
Bowie
Esther M
EM
Folk
James C
JC
Barnes
Charles H
CH
D000328:Adult; D015766:Albendazole / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001826:Body Fluids; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D020019:Neurocysticercosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D010672:Phenytoin / Q000627:therapeutic use; D011239:Prednisolone / Q000009:adverse effects; D012164:Retinal Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D014222:Triamcinolone Acetonide / Q000009:adverse effects; D017287:Ventriculoperitoneal Shunt; D014786:Vision Disorders / Q000209:etiology; D014792:Visual Acuity
D000927:Anticonvulsants; D000981:Antiprotozoal Agents; D005938:Glucocorticoids; D010672:Phenytoin; D011239:Prednisolone; D015766:Albendazole; D014222:Triamcinolone Acetonide